Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Don't get rid of mercury yet, says AHA (American Heart Association)

This article was originally published in Clinica

Executive Summary

Replacing mercury sphygmomanometers with more modern aneroid or electronic instruments is not necessarily a good idea, according to an advisory statement by the American Heart Association's Council for High Blood Pressure Research. The newer types of instrument have a number of drawbacks compared with the "gold standard" mercury gravity sphygmomanometer, the Council says in the journal, Hypertension (February).

You may also be interested in...



Vemedia Acquires GSK Brands In Italy, Strikes Deal For GI Product In Spain

GSK has offloaded a further two brands, this time in Italy, giving Netherlands-based Vemedia the opportunity to bolster its portfolio in the country. Vemedia has also added to its offering in Spain by striking a separate deal with Puerto Galiano.

EU Preserves Status Quo On Drugs Under Additional Monitoring

The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.

Meitheal Gets US Enoxaparin Approval

Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.

Topics

UsernamePublicRestriction

Register

MT070043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel